Paul J. Phojanakong

This study uses deep learning and physics-based modeling to engineer a CD27 variant that improves the efficacy of CD70-targeting CAR T-cells across multiple cancer models.

The paper investigates the CD48-CD244 axis in multiple myeloma, showing CD48 enhances NK-cell activation but contributes to NK exhaustion and poor prognosis.

This study identifies PAD4 substrates and their citrullination effects, showing PAD4 induces cell migration and generates citrullinated peptides that can trigger autoantibodies.

This study shows that affinity-matured CD72-targeting nanobody CAR T-cells improve in vitro efficacy against CD72-low tumors but show limited in vivo benefit, while CD72 expression remains stable after CD19 resistance in B-cell malignancies.

This paper develops dual-antigen targeting CAR-T cells against CD70 and active integrin β2 to overcome AML antigen heterogeneity and reduce off-tumor toxicity.

This paper engineers CCL27 mutants to enhance CAR T-cell efficacy against multiple myeloma by targeting CCR10, achieving results comparable to BCMA CAR-Ts.

Structure-optimized CD27-based CAR-T cells targeting CD70 show >80-fold improved expansion in vivo and offer a potential therapy for high-risk multiple myeloma patients.

The paper uses chemoproteomics to identify immunogenic cell surface substrates of CK2α in the tumor microenvironment, showing that extracellular phosphorylation can generate immunogenic antigens.